{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T04:10:15Z","timestamp":1748923815165,"version":"3.41.0"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T00:00:00Z","timestamp":1744416000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>A wide range of effective antiretroviral therapy (ART) regimens with favourable side effects are available. More than 70% of HIV care costs in the Netherlands are attributed to ART. We developed an ART algorithm to proactively switch virologically suppressed individuals to a more cost-effective HIV treatment.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This prospective study implemented our ART algorithm in two large Dutch HIV clinics, where a pharmacist screened ART regimens for 1 year. Individuals were considered suitable for a switch if their current ART exceeded \u20ac600 per month, considering renal function and\/or tubular toxicity, hepatitis B status, and resistance history. If eligible, advice with a switch proposal was recorded in the patient file. The objective was to investigate the acceptance of the proposal and the effect of proactive switching on the total costs of ARTs.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Findings<\/jats:title>\n                  <jats:p>Of 1596 people living with HIV, 840 (52.6%) were eligible. Prescribers accepted 81.1% of the switch proposals, and 84.9% of eligible individuals agreed to the proposed switch. Ultimately, 558 individuals accepted the new ART regimen proposal, with doravirine\/tenofovir disoproxil fumarate\/lamuvidine (DOR\/TDF\/3TC) being the most prescribed (61.6%). The switch led to significant cost savings, reducing annual ART expenditure from \u20ac10\u200a923 to \u20ac8580 per eligible individual, totalling almost \u20ac2 million (\u221221.4%) in savings annually.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Interpretation<\/jats:title>\n                  <jats:p>Our ART algorithm demonstrated high acceptance by prescribers and people with HIV, leading to substantial cost savings. The algorithm can be easily implemented in other HIV clinics to offer even more significant cost savings to Dutch healthcare payers.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkaf117","type":"journal-article","created":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T10:46:26Z","timestamp":1744454786000},"page":"1656-1664","source":"Crossref","is-referenced-by-count":0,"title":["Optimising antiretroviral therapy through a proactive treatment algorithm: a cost-effective strategy in Dutch healthcare for people with HIV"],"prefix":"10.1093","volume":"80","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-1551-7524","authenticated-orcid":false,"given":"P","family":"Oosterhof","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy, OLVG Hospital , Amsterdam ,","place":["The Netherlands"]},{"name":"Department of Pharmacy, Radboudumc Research Institute for Medical Innovation (RIMI), Radboud University Medical Center , Nijmegen ,","place":["The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"van Luin","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Meander Medical Center , Amersfoort ,","place":["The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K","family":"Grintjes","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Radboud Center for Infectious Diseases, Radboud University Medical Center , Nijmegen ,","place":["The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N","family":"van der Meche","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Internal Medicine, OLVG , Amsterdam ,","place":["The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6233-6410","authenticated-orcid":false,"given":"R","family":"van Crevel","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Radboud Center for Infectious Diseases, Radboud University Medical Center , Nijmegen ,","place":["The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K","family":"Brinkman","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Internal Medicine, OLVG , Amsterdam ,","place":["The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7279-2818","authenticated-orcid":false,"given":"D M","family":"Burger","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Radboudumc Research Institute for Medical Innovation (RIMI), Radboud University Medical Center , Nijmegen ,","place":["The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,4,12]]},"reference":[{"volume-title":"HIV Antiretroviral Therapy","year":"2022","author":"Kemnic","key":"2025060219522722100_dkaf117-B1"},{"author":"van Sighem","key":"2025060219522722100_dkaf117-B2"},{"key":"2025060219522722100_dkaf117-B3","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1097\/QAD.0b013e32834dce6e","article-title":"Newer drugs and earlier treatment: impact on lifetime cost of care for HIV-infected adults","volume":"26","author":"Sloan","year":"2012","journal-title":"AIDS"},{"author":"RIVM","key":"2025060219522722100_dkaf117-B4"},{"author":"(NVHB) NVvHB","key":"2025060219522722100_dkaf117-B5"},{"key":"2025060219522722100_dkaf117-B6","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1080\/03007995.2016.1227776","article-title":"Quality of life of HIV-infected patients who switch antiretroviral medication due to side effects or other reasons","volume":"32","author":"Maiese","year":"2016","journal-title":"Curr Med Res Opin"},{"issue":"4 Suppl 3","key":"2025060219522722100_dkaf117-B7","doi-asserted-by":"publisher","first-page":"19497","DOI":"10.7448\/IAS.17.4.19497","article-title":"Predicted savings to the UK national health service from switching to generic antiretrovirals, 2014-2018","volume":"17","author":"Hill","year":"2014","journal-title":"J Int AIDS Soc"},{"key":"2025060219522722100_dkaf117-B8","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.medmal.2016.01.003","article-title":"Generic antiretroviral drugs and HIV care: an economic review","volume":"46","author":"Yazdanpanah","year":"2016","journal-title":"Med Mal Infect"},{"issue":"Suppl 1","key":"2025060219522722100_dkaf117-B9","doi-asserted-by":"publisher","first-page":"S35","DOI":"10.1007\/s40258-014-0145-2","article-title":"A systematic review of physicians\u2019 and pharmacists\u2019 perspectives on generic drug use: what are the global challenges?","volume":"13","author":"Toverud","year":"2015","journal-title":"Appl Health Econ Health Policy"},{"key":"2025060219522722100_dkaf117-B10","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s40801-016-0070-9","article-title":"Patients\u2019 willingness to take multiple-tablet antiretroviral therapy regimens for treatment of HIV","volume":"3","author":"Engelhard","year":"2016","journal-title":"Drugs Real World Outcomes"},{"key":"2025060219522722100_dkaf117-B11","doi-asserted-by":"publisher","DOI":"10.1177\/2325958218822304","article-title":"Desimplification of single tablet antiretroviral (ART) regimens-a practical cost-savings strategy?","volume":"18","author":"Krentz","year":"2019","journal-title":"J Int Assoc Provid AIDS Care"},{"key":"2025060219522722100_dkaf117-B12","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1111\/hiv.12578","article-title":"Patient perspectives on de-simplifying their single-tablet co-formulated antiretroviral therapy for societal cost savings","volume":"19","author":"Krentz","year":"2018","journal-title":"HIV Med"},{"key":"2025060219522722100_dkaf117-B13","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.12998\/wjcc.v7.i14.1814","article-title":"Desimplification to multi-tablet antiretroviral regimens in human immunodeficiency virus-type 1 infected adults: a cohort study","volume":"7","author":"Rossi","year":"2019","journal-title":"World J Clin Cases"},{"key":"2025060219522722100_dkaf117-B14","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1111\/fcp.12363","article-title":"Comparison of adherence to generic multi-tablet regimens vs. brand multi-tablet and brand single-tablet regimens likely to incorporate generic antiretroviral drugs by breaking or not fixed-dose combinations in HIV-infected patients","volume":"32","author":"Rwagitinywa","year":"2018","journal-title":"Fundam Clin Pharmacol"},{"author":"Zorginstituut Nederland","key":"2025060219522722100_dkaf117-B15"},{"key":"2025060219522722100_dkaf117-B16","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s13561-014-0015-5","article-title":"Economic impact of HIV\/AIDS: a systematic review in five European countries","volume":"4","author":"Trapero-Bertran","year":"2014","journal-title":"Health Econ Rev"},{"author":"Stichting Farmaceutische Kengetallen (SFK)","key":"2025060219522722100_dkaf117-B17"},{"key":"2025060219522722100_dkaf117-B18"},{"key":"2025060219522722100_dkaf117-B19","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1097\/QAI.0000000000002923","article-title":"Brief report: patients\u2019 experiences and opinions after desimplification of their single-tablet regimens for the treatment of HIV infection: a survey in a multicentre cohort","volume":"90","author":"Su\u00e1rez-Garc\u00eda","year":"2022","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2025060219522722100_dkaf117-B20","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1111\/hiv.13655","article-title":"De-simplifying antiretroviral therapy from a single-tablet to a two-tablet regimen: acceptance, patient-reported outcomes, and cost savings in a multicentre study","volume":"25","author":"Oosterhof","year":"2024","journal-title":"HIV Med"},{"key":"2025060219522722100_dkaf117-B21","doi-asserted-by":"publisher","first-page":"e16813","DOI":"10.1097\/MD.0000000000016813","article-title":"DOLAMA study: effectiveness, safety and pharmacoeconomic analysis of dual therapy with dolutegravir and lamivudine in virologically suppressed HIV-1 patients","volume":"98","author":"Hidalgo-Tenorio","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"2025060219522722100_dkaf117-B22","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1007\/s40121-023-00848-4","article-title":"Comparing real-world healthcare costs associated with single-tablet regimens for HIV-1: the 2-drug regimen Dolutegravir\/lamivudine vs. standard 3- or 4-drug regimens","volume":"12","author":"Priest","year":"2023","journal-title":"Infect Dis Ther"},{"key":"2025060219522722100_dkaf117-B23","doi-asserted-by":"publisher","first-page":"e0117214","DOI":"10.1371\/journal.pone.0117214","article-title":"Perception of antiretroviral generic medicines: one-day survey of HIV-infected patients and their physicians in France","volume":"10","author":"Jacomet","year":"2015","journal-title":"PLoS One"},{"volume-title":"The Netherlands: Country Health Profile 2021, State of Health in the EU","year":"2021","author":"European Observatory on Health Systems and Policies (OECD)","key":"2025060219522722100_dkaf117-B24"},{"key":"2025060219522722100_dkaf117-B25","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s11606-010-1275-3","article-title":"Decision-making role preferences among patients with HIV: associations with patient and provider characteristics and communication behaviors","volume":"25","author":"Kumar","year":"2010","journal-title":"J Gen Intern Med"},{"key":"2025060219522722100_dkaf117-B26","doi-asserted-by":"publisher","first-page":"e046212","DOI":"10.1136\/bmjopen-2020-046212","article-title":"Can we talk about price with patients when choosing antiretroviral therapy? A survey with people living with HIV and prescribers in France","volume":"11","author":"Papot","year":"2021","journal-title":"BMJ Open"},{"key":"2025060219522722100_dkaf117-B27","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1111\/imj.12805","article-title":"The art of prescribing: negotiating the decision of generic or branded medications","volume":"45","author":"Grant","year":"2015","journal-title":"Intern Med J"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/6\/1656\/62921244\/dkaf117.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/6\/1656\/62921244\/dkaf117.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T23:52:35Z","timestamp":1748908355000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/80\/6\/1656\/8112668"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,12]]},"references-count":27,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,4,12]]},"published-print":{"date-parts":[[2025,6,3]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkaf117","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"type":"print","value":"0305-7453"},{"type":"electronic","value":"1460-2091"}],"subject":[],"published-other":{"date-parts":[[2025,6]]},"published":{"date-parts":[[2025,4,12]]}}}